
zzso zzso growth factor zzso is a key zzso of zzso and pathological zzso All solid tumors are dependent on pathological zzso and zzso therapy has demonstrated clinical benefit in breast, zzso zzso zzso and zzso zzso Central nervous system zzso are common in many of these tumor zzso An increased risk of bleeding has been reported with zzso therapy, but the risk of zzso bleeding is unknown with this type of zzso We reviewed the available data to investigate the risk of zzso bleeding with zzso therapy in the presence and absence of zzso zzso The zzso and zzso databases and the Proceedings of the American Society of Clinical Oncology zzso annual meetings were searched for articles, zzso and presentations of clinical zzso We identified 57 trials examining the safety and efficacy of zzso therapy in a total of zzso zzso Four trials examined the use of zzso therapy in treating patients with brain zzso The presence of zzso zzso was a stated exclusion criterion in zzso of zzso The rate of zzso bleeding was zzso We conclude that there is no trial evidence that zzso therapy zzso an increased risk of zzso zzso even in the presence of zzso zzso Future trials of zzso therapy should not exclude patients with controlled zzso zzso at zzso 

